Vasomotor Symptoms Market Demands and Growth Predication 2020-2027

Posted by vinit sawant on February 8th, 2021

The global vasomotor symptoms market is driven by several factors, such as rising older female population, rising initiatives by public and private organizations to create awareness regarding vasomotor symptoms management options, increasing product launches, and a number of clinical trials by the prominent players in the market.

According to MRFR analysis, the Global Vasomotor Symptoms Market is expected to register a CAGR of 7.27% from 2020 to 2027 and hold a value of USD 8,189 Million till 2027.

A lot of market players are dominating the global vasomotor symptoms market. The prominent players are involved in strategic agreements, product launches, and joint ventures to sustain their market positions. For instance, in October 2018, Therapeutics (US) received FDA approval for its first bio identical hormone therapy BIJUVA, a combination of estradiol and progesterone for moderate to severe vasomotor symptoms associated with menopause.

Segmentation

Global Vasomotor Symptoms Market has been segmented based on the Therapy Type and Distribution Channel.

The market, based on therapy type, has been segmented into hormonal and non-hormonal. The market, based on hormonal therapy, has been further divided into estrogen, progesterone, and combination. The market, based on hormonal therapy, held a major share in 2019 owing to the widespread use and high preference rate. The market, based on non-hormonal therapy, has been further divided into antidepressants and others.

The hospital pharmacies segment held the majority share of the market in 2019 owing to the increasing number of in-visit patient admissions, whereas the online stores segment is projected to be the fastest-growing segment during the study period owing to the increasing preference of this distribution channels owing to the widespread availability and rise in awareness regarding the e-commerce channels.